비소세포성 폐암의 방사선치료 성적
Treatment of Unresectable Non-Small-Cell Lung Cancer with Curative Radiotherapy

대한치료방사선과학회지 1984년 2권 2호 p.203 ~ p.211

김일한(Kim Il-Han) - 서울대학교 의과대학 방사선과학교실
하성환(Ha Sung-Whan) - 서울대학교 의과대학 방사선과학교실
박찬일(Park Charn-Il) - 서울대학교 의과대학 방사선과학교실
심영수(Shim Young-Soo) - 서울대학교 의과대학 내과학교실
김노경(Kim Noe-Kyeong) - 서울대학교 의과대학 내과학교실
김근열(Kim Keun-Youl) - 서울대학교 의과대학 내과학교실
한용철(Han Yong-Chul) - 서울대학교 의과대학 내과학교실

Abstract

From 1979 to 1982, 80 patients with unresectable non-small-cell lung cancer without metastasis were treated with high-dose radiotherapy to the primary and to regional lymph nodes with or without supraclavicular lymphatic in the Department of Therapeutic radiology, Seoul National University Hospital.
Of these, 56 patients (70%) were completely evaluable, and 59 patients (74%) had squamous cell carcinoma, 13% large cell undifferentiated carcinoma and 8% Aden carcinoma. 21 patients (26%) had Stage Ⅱ and 59 patients (74%) had Stage Ⅲ.
The complete and partial response rate in the high-dose (~ 6,000rad) radiotherapy was 70% with 19% complete response. 69 patients (86%) failed in the treatment, by the failure pattern, 64% had local failure alone, 35% had local failure and distant metastasis and 1% had distant metastasis alone. The failure rate in the thorax was 76% in squamous cell carcinoma, 40% in Aden carcinoma and 20% in large cell undifferentiated carcinoma. Preliminary result shows that actuarial survival at 1, 2 and 3 years were 56%, 26% and 20% in overall patients and 64%, 37% and 21% in Stage Ⅱ and 54%, 21% and 18% in Stage Ⅲ, respectively. Overall median survival was 14 months; 17 months in Stage Ⅱ and 13 months in Stage Ⅲ. 8 patients (10%) have lived a minimum of 2 years with no evidence of disease.
There was no fatal complication confirmed to be induced by radiotherapy, so definitive high-dose radiotherapy was tolerated well without major problems and resulted in good local control and survival.

키워드

원문 및 링크아웃 정보
등재저널 정보
주제코드
주제명(Target field)
연구대상(Population)
연구참여(Sample size)
대상성별(Gender)
질병특성(Condition Category)
연구환경(Setting)
연구설계(Study Design)
연구기간(Period)
중재방법(Intervention Type)
중재명칭(Intervention Name)
키워드(Keyword)
유효성결과(Recomendation)
Actuarial survival at 1, 2 and 3 years were 56%, 26% and 20% and 64%, 37% and 21% in Stage Ⅱ and 54%, 21% and 18% in Stage Ⅲ, respectively. Overall median survival was 14 months; 17 months in Stage Ⅱ and 13 months in Stage Ⅲ.
연구비지원(Fund Source)
근거수준평가(Evidence Hierarchy)
출판년도(Year)
참여저자수(Authors)
대표저자
DOI
KCD코드
ICD 03
건강보험코드